MRUS
Merus N.V. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q4 2025 | 1 | -19 | 837 | $75,330 | — | −19 |
| Q3 2025 | 19 | +1 | 12.61M | $1.19B | +1 | — |
| Q2 2025 | 15 | +2 | 16.75M | $880.83M | +2 | — |
| Q1 2025 | 10 | -1 | 7.37M | $310.31M | — | −1 |
| Q4 2024 | 11 | 0 | 7.78M | $327.28M | — | — |
| Q3 2024 | 10 | 0 | 7.49M | $374.22M | — | — |
| Q2 2024 | 10 | — | 6.42M | $379.66M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Simplex Trading, Llc | 837 | — | $75,330 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Fidelity (FMR) | $264.65M | was 0.0% |
| BlackRock | $204.50M | was 0.0% |
| JPMorgan Chase | $142.36M | was 0.0% |
| Goldman Sachs Group | $112.55M | was 0.0% |
| T. Rowe Price | $102.36M | was 0.0% |
| Millennium Management | $65.81M | was 0.1% |
| Citadel Advisors | $57.86M | was 0.0% |
| Adage Capital Partners | $56.49M | was 0.1% |
| Wellington Management | $43.22M | was 0.0% |
| Soros Fund Management | $38.13M | was 0.9% |
| The Vanguard Group | $26.63M | was 0.0% |
| Point72 Asset Management | $23.98M | was 0.1% |
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.